Scandinavian ChemoTech AB (CMOTEC B) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a growth in Net Sales of 55.38%, the company declared Very Positive results in Jun 25

The company has declared positive results for the last 7 consecutive quarters
OPERATING CASH FLOW(Y) Highest at SEK -9.48 MM
DEBTORS TURNOVER RATIO(HY) Highest at 2.86%
OPERATING PROFIT(Q) Highest at SEK -0.1 MM

Risky -

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 102 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.69

Return on Equity

-140.47%

Price to Book

16.53

Revenue and Profits:

Net Sales:

4 Million

(Quarterly Results - Jun 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

8.82%

6 Months

72.09%

1 Year

135.67%

2 Years

44.76%

3 Years

-30.99%

4 Years

-78.46%

5 Years

-65.15%

Scandinavian ChemoTech AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

65.67%

EBIT Growth (5y)

7.58%

EBIT to Interest (avg)

-13.78

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.28

Sales to Capital Employed (avg)

1.28

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

50.88

EV to EBIT

-11.97

EV to EBITDA

-15.35

EV to Capital Employed

66.27

EV to Sales

11.27

PEG Ratio

Dividend Yield

ROCE (Latest)

-553.46%

ROE (Latest)

-486.78%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 52.00% vs 25.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 72.73% vs -3.13% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.80",
          "val2": "2.50",
          "chgp": "52.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.10",
          "val2": "-2.00",
          "chgp": "95.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.90",
          "val2": "-3.30",
          "chgp": "72.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-153.30%",
          "val2": "-1,025.50%",
          "chgp": "87.22%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 135.71% vs 460.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 35.07% vs 7.05% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.60",
          "val2": "2.80",
          "chgp": "135.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.50",
          "val2": "-20.00",
          "chgp": "37.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "1.40",
          "chgp": "-14.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.70",
          "val2": "-21.10",
          "chgp": "35.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,932.80%",
          "val2": "-7,136.40%",
          "chgp": "520.36%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

3.80

2.50

52.00%

Operating Profit (PBDIT) excl Other Income

-0.10

-2.00

95.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-0.90

-3.30

72.73%

Operating Profit Margin (Excl OI)

-153.30%

-1,025.50%

87.22%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 52.00% vs 25.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 72.73% vs -3.13% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

6.60

2.80

135.71%

Operating Profit (PBDIT) excl Other Income

-12.50

-20.00

37.50%

Interest

1.20

1.40

-14.29%

Exceptional Items

0.00

Consolidate Net Profit

-13.70

-21.10

35.07%

Operating Profit Margin (Excl OI)

-1,932.80%

-7,136.40%

520.36%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 135.71% vs 460.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 35.07% vs 7.05% in Dec 2023

All Annual Results

Company CV

About Scandinavian ChemoTech AB

Scandinavian ChemoTech AB

Pharmaceuticals & Biotechnology

Scandinavian ChemoTech AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused on cancer treatment and manufactures specialized medical equipment. The Company's product IQWave is an electrochemotherapy (ECT) device. The IQWave system enhances the effects of the chemotherapeutic substance by opening up small pores in the tumor cells, giving the injected chemotherapeutic substance (no more than 15 IU of bleomycin) direct access to the DNA of the target cells. Among the product's applications are hypernephroma, kaposi sarcoma, transitional cell carcinoma, head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma. The treatment can be used for cutaneous as well as subcutaneous tumors.

Company Coordinates

Company Details

Medicon Village, Scheelevagen 2 , LUND None : 223 63

Tel:

http://chemotech.se/

Registrar Details